$0.51
0.0182[3.70%]
At close: Apr 24
$0.51
0[0.00%]
After Hours: 7:54PM EDT
BioVie Stock (NASDAQ:BIVI), Analyst Ratings, Price Targets, Predictions
BioVie Inc has a consensus price target of $12.75, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, Cantor Fitzgerald, and Cantor Fitzgerald on November 30, 2023, August 22, 2023, and July 18, 2023. With an average price target of $9 between Oppenheimer, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied 1664.71% upside for BioVie Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Cantor Fitzgerald
EF Hutton
B. Riley Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for BioVie
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/30/2023 | BIVI | Buy Now | BioVie | $0.51 | 880.39% | Oppenheimer | Jay Olson | $12 → $5 | Maintains | Outperform | Get Alert |
| 08/22/2023 | BIVI | Buy Now | BioVie | $0.51 | 2056.86% | Cantor Fitzgerald | Charles Duncan | → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 07/18/2023 | BIVI | Buy Now | BioVie | $0.51 | 2056.86% | Cantor Fitzgerald | Charles Duncan | → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 05/17/2023 | BIVI | Buy Now | BioVie | $0.51 | 2056.86% | Cantor Fitzgerald | Charles Duncan | → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 05/17/2023 | BIVI | Buy Now | BioVie | $0.51 | 2252.94% | Oppenheimer | Jay Olson | → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 02/14/2023 | BIVI | Buy Now | BioVie | $0.51 | 2252.94% | Oppenheimer | Jay Olson | → $12 | Reiterates | → Outperform | Get Alert |
| 09/28/2022 | BIVI | Buy Now | BioVie | $0.51 | 1468.63% | EF Hutton | Constantine Davides | $14 → $8 | Maintains | Buy | Get Alert |
| 07/22/2022 | BIVI | Buy Now | BioVie | $0.51 | 1272.55% | Cantor Fitzgerald | Charles Duncan | → $7 | Initiates | → Overweight | Get Alert |
| 03/17/2022 | BIVI | Buy Now | BioVie | $0.51 | 2645.1% | EF Hutton | Constantine Davides | $9 → $14 | Maintains | Buy | Get Alert |
| 03/15/2022 | BIVI | Buy Now | BioVie | $0.51 | 1664.71% | Oppenheimer | Jay Olson | → $9 | Initiates | → Outperform | Get Alert |
| 11/30/2021 | BIVI | Buy Now | BioVie | $0.51 | 5194.12% | B. Riley Securities | Mayank Mamtani | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for BioVie (BIVI)?
The latest price target for BioVie (NASDAQ: BIVI) was reported by Oppenheimer on November 30, 2023. The analyst firm set a price target for $5.00 expecting BIVI to rise to within 12 months (a possible 880.39% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioVie (BIVI)?
The latest analyst rating for BioVie (NASDAQ: BIVI) was provided by Oppenheimer, and BioVie maintained their outperform rating.
When was the last upgrade for BioVie (BIVI)?
There is no last upgrade for BioVie.
When was the last downgrade for BioVie (BIVI)?
There is no last downgrade for BioVie.
When is the next analyst rating going to be posted or updated for BioVie (BIVI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioVie was filed on November 30, 2023 so you should expect the next rating to be made available sometime around November 30, 2024.
Is the Analyst Rating BioVie (BIVI) correct?
While ratings are subjective and will change, the latest BioVie (BIVI) rating was a maintained with a price target of $12.00 to $5.00. The current price BioVie (BIVI) is trading at is $0.51, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.